BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals (VGXP), a developer of DNA vaccines against cancer and infectious diseases, presented today non-human primate study data from both its PENNVAX™ HIV Vaccine Program and its patented CELLECTRA® DNA Delivery technology in two presentations at the AIDS Vaccine 2008 Conference currently taking place in Cape Town, South Africa.
